Logo1
ICCS - 2023 38th International Clinical Cytometry Society Annual Meeting (PACE Only)
Mr pencil

How would you like your name to appear on your certificate?



What activities did you attend at the event?
Agreement
By completing this form, you attest that you have participated in all selected activities in thier entirety.
Please rate the following:
The program was relevant to my work.
Content matched stated objectives.
Usefulness of handouts/AV/technology.
Quality of facilities and facility accommodations.
How well did the educational sessions give a balanced view of therapeutic options, including the use of generic names?
If you rated any of the above questions with 'fair,' 'poor,' 'disagree,' or 'strongly disagree' please explain in detail (e.g. session title, speaker name, situtation):
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
Objective 1: Understand the scientific basis of clinical flow cytometry and its applications in the diagnosis of hematologic disease.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
Objective 2: Become familiar with the latest technical advances in flow cytometry that can be applied in their own laboratories.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
Did this program improve your Skill or Strategy in your role or contribution as a member of the healthcare team?
If no, why not?
Do you believe your participation in this activity will positively impact your healthcare team?
If yes, how?
If no, why not?
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
The instructor used technology effectively
Review College of American Pathologists Accreditation focusing on new items and updates
Update on the status of CLSI Guideline H43 guidelines: a guideline of the immunophenotypic analysis of neoplastic hematolymphoid cells
Utilize telepathology to provide diagnostic Services to under served places, in building clinical and research capacity
Update the status of the current practice of clinical flow cytometry and help laboratory departments, directors, and managers make appropriate, cost-effective staffing decisions
The instructor used technology effectively
Introduce the high-resolution single-cell analysis technology that help to open up new avenues for the development of more efficacious yet safe CAR-T cell therapy
Update on recent research and applications of flow cytometry T- cell analysis in Hemophagocytic Lymphohistiocytosis
Explore the utility of flow cytometry lymphocyte subset analysis in understanding CNS autoimmunity
The instructor used technology effectively
Provide an overview of Mixed Phenotype Acute Leukemia in the light of recent understanding of molecular genetics of these perplexing entities
The instructor used technology effectively
Optimize sample preparation in the current clinical flow cytometry practice and with the help of automation
The instructor used technology effectively
Share experience in the implemmentation of spectral cytometry in clinical lab and demonstrate its applications in patient samples
The instructor used technology effectively
Share experience in the set up of monocyte partition study, and illustrate the validation process
The instructor used technology effectively
Overview of the concepts,  methods and practical considerations of Computational High-Dimensional Flow Cytometry Analysis
Interpret MDS and AML heterogeneity  through Computational Clustering Analysis for Dissecting Abnormal Myeloid Hematopoiesis
Demonstrate Phenotypic Heterogeneity during ALL Disease Progression by Computational Dimensionality-Reduction Analysis
The instructor used technology effectively
Differentiate residual AML from underlying MDS and clonal hematopoiesis in AML post threapy, and correctly interpret phenotypic information pertinent to proper patient management
Assess Leukemia Stem Cells in Acute Myeloid Leukemia in understanding tumor resistance and guiding targeted therapy
Break down the complexity of leukemogenesis using Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia
The instructor used technology effectively
 Highlight and interpret the critical elements in assay validation, through practical examples
The instructor used technology effectively
Overview the basic principles and fundamental methology in  Computational and Artificial Intelligence in Clinical Cytometry
The instructor used technology effectively
Introduce EuroFlow Approach for Automated Data Analysis and Reporting for MRD Monitoring: Using BCP-ALL and Multiple Myeloma as examples for illustration
The instructor used technology effectively
Illustrate how to utilize the flow cytometry software to set up the analysis template, for better data assessment and reporting
The instructor used technology effectively
Provide an update on recent research in Immunophenotyping of Mast Cells and  Immune Cells in Mastocytosis, focusing on the aspect related to Clinical Utility
Facilitate the differential diagnosis between Blastoid High-Grade B-Cell Lymphoma and B-Lymphoblastic Leukemia/Lymphoma by recognizing their Immunophenotypic characteristics
Uncover the Phenotype-Genotype Link, facilitating proper work-up of acute leukemia
Update on Immunophenotyping of T/NK- Cell Lymphomas that enhance our ability to recognize neoplastic T/NK cells
Please tell us about any sessions you found particularly good or bad.
Please tell us about any objectives you feel we accomplished well or poorly.
Please tell us about any presenters you found particularly good or bad.
Please answer the following:
Do you believe this activity was appropriate for the scope of your professional activities?
Was the educational content scientifically sound?
If faculty spoke about off-label or investigational uses of a product, was that information disclosed to you?
Was the mode of education effective to learning?
If you answered "No" to any of the above questions, please explain.
Did you perceive any product/service/company/commercial bias in any educational session you attended or materials you received?
If you answered "Yes" to the above question, please detail the situation below (e.g. session title, speaker name):
Were you solicited by sales personnel in an educational room (other areas do not matter) while you attended this educational activity?
If you answered "Yes" to the above question, please explain in detail (e.g. who, when, where):
How much did you learn as a result of this education program?
What specifically did you learn during this activity that you intend to integrate into your practice?

What questions have arisen in your practice for which you need answers/strategies that you can implement?

What patient/client problems or patient/client challenges do you feel you are not able to address appropriately or to your satisfaction?
What problems are your patients/clients communicating to you that need attention or follow up?

Are you interested in basic, intermediate or advanced level trainings?

What barriers might you have that would interfere with implementation of new information learned from this training?

How can this training (the overall meeting) be improved to better impact competence, performance and/or patient/client outcomes?

Additional comments:

Mr question
Provided by amedco